RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus (original) (raw)

• Feingold KR, Grunfeld C. Diabetes and dyslipidemia. Endotext [Internet]. 2019 Jan 3.
• Spratt KA. Managing diabetic dyslipidemia: aggressive approach. J Am Osteopathic Assoc. 2009;109(5_suppl_1):S2–7.
  Google Scholar
• Gowtham K, Gandhe MB, Salwe KJ, Srinivasan AR. HDL/LDL ratio as a risk factor in type 2 diabetes mellitus. Adv Lab Med Int. 2012;2:9–18.
  Google Scholar
• Chhatriwala MN, Patel MP, Patel DS, Shah HN. Relationship between dyslipidemia and glycemic status in type-2 diabetes mellitus. Natl J Lab Med. 2019;8(4):BO01–4.
  Google Scholar
• Chandra KS, Bansal M, Nair T, Iyengar SS, Gupta R, Manchanda SC, et al. Consensus statement on management of dyslipidemia in Indian subjects. Indian Heart J. 2014;66(Suppl 3):S1.
  PubMed Google Scholar
• Schofield JD, Liu Y, Rao-Balakrishna P, Malik RA, Soran H. Diabetes dyslipidemia. Diabetes Therapy. 2016;7(2):203–19.
  CAS PubMed PubMed Central Google Scholar
• Puri R, Mehta V, Iyengar SS, Narasingan SN, Duell PB, Sattur GB, et al. Lipid Association of India expert consensus statement on management of dyslipidemia in Indians 2020: Part III. J Assoc Phys India. 2020;68(11 [Special]):8–9.
  Google Scholar
• Khan MA, Hashim MJ, King J, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes—global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020 Mar;10(1):107–11.
• Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157:107843.
  PubMed Google Scholar
• The World Bank [Website]. Diabetes prevalence. Accessed on 04th December 2019. Available from: https://data.worldbank.org/indicator/SH.STA.DIAB.ZS?end=2019&name_desc=false&start=2019&type=shaded&view=map&year=2019.
• International Diabetes Federation. Updated on: 3rd March 2020. Cited on: 24th November 2020. Available from: https://idf.org/our-network/regions-members/south-east-asia/members/94-india.html.
• Tandon N, Anjana RM, Mohan V, Kaur T, Afshin A, Ong K, et al. The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990–2016. Lancet Glob Health. 2018;6(12):e1352–62.
  Google Scholar
• Parikh RM, Joshi SR, Menon PS, Shah NS. Prevalence and pattern of diabetic dyslipidemia in Indian type 2 diabetic patients. Diabetes Metab Syndr. 2010;4(1):10–2.
  Google Scholar
• Joshi SR, Anjana RM, Deepa M, Pradeepa R, Bhansali A, et al. Prevalence of dyslipidemia in urban and rural India: the ICMR–INDIAB Study. PLoS ONE. 2014;9(5):e96808. https://doi.org/10.1371/journal.pone.0096808.
  Article CAS PubMed PubMed Central Google Scholar
• Mithal A, Majhi D, Shunmugavelu M, Talwarkar PG, Vasnawala H, Raza AS. Prevalence of dyslipidemia in adult Indian diabetic patients: a cross sectional study (SOLID). Indian J Endocrinol Metabol. 2014;18(5):642.
  Google Scholar
• Dayakar E, Sree CS, Sanjay E. Study on the prevalence of dyslipidemia in type 2 diabetes mellitus. Int J Adv Med. 2019;6:786–9.
  Google Scholar
• Bulut T, Demirel F, Metin A. The prevalence of dyslipidemia and associated factors in children and adolescents with type 1 diabetes. J Pediatr Endocrinol Metab. 2017;30(2):181–7.
  PubMed Google Scholar
• Shah N, Khadilkar A, Gondhalekar K, Khadilkar V. Prevalence of dyslipidemia in Indian children with poorly controlled type 1 diabetes mellitus. Pediatr Diabetes. 2020;21(6):987–94.
  CAS PubMed Google Scholar
• Claypool KT, Chung MK, Deonarine A, Gregg EW, Patel CJ. Characteristics of undiagnosed diabetes in men and women under the age of 50 years in the Indian subcontinent: the National Family Health Survey (NFHS-4)/Demographic Health Survey 2015–2016. BMJ Open Diab Res Care. 2020;8(1):e000965.
  PubMed PubMed Central Google Scholar
• Najafipour H, Shokoohi M, Yousefzadeh G, Azimzadeh BS, Kashanian GM, Bagheri MM, et al. Prevalence of dyslipidemia and its association with other coronary artery disease risk factors among urban population in Southeast of Iran: results of the Kerman coronary artery disease risk factors study (KERCADRS). J Diabetes Metab Disord. 2016;15(1):49.
  PubMed PubMed Central Google Scholar
• Artha IM, Bhargah A, Dharmawan NK, Pande UW, Triyana KA, Mahariski PA, et al. High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus. Vasc Health Risk Manag. 2019;15:149.
  PubMed PubMed Central Google Scholar
• Halcox J, Misra A. Type 2 diabetes mellitus, metabolic syndrome, and mixed dyslipidemia: how similar, how different, and how to treat? Metab Syndr Relat Disord. 2015;13(1):1–21.
  CAS PubMed Google Scholar
• Simha V. Management of hypertriglyceridemia. BMJ. 2020 Oct12;371:m3109.
• Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5(3):150–9.
  CAS Google Scholar
• Panikar V. Chapter 101: mixed dyslipidemia. Medicine Update. 2008;18:764.
  Google Scholar
• Kei A, Miltiadous G, Bairaktari E, Hadjivassiliou M, Cariolou M, Elisaf M. Dysbetalipoproteinemia: two cases report and a diagnostic algorithm. World J Clin Cases. 2015;3(4):371.
  PubMed PubMed Central Google Scholar
• Varghese MJ. Familial hypercholesterolemia: a review. Ann Pediatr Cardiol. 2014;7(2):107.
  PubMed PubMed Central Google Scholar
• Gaddi A, Cicero AF, Odoo FO. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manag. 2007;3(6):877.
  CAS PubMed PubMed Central Google Scholar
• Koopal C, Marais AD, Visseren FL. Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder. Curr Opin Endocrinol Diabetes Obes. 2017;24(2):133–9.
  CAS PubMed Google Scholar
• Handelsman Y, Jellinger PS, Guerin CK, Bloomgarden ZT, Brinton EA, Budoff MJ, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm—2020 executive summary. Endocr Pract. 2020;26(10):1196–224.
  PubMed Google Scholar
• Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. Am J Cardiol. 2012;110(6):823–5.
  CAS PubMed Google Scholar
• Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP. Primary and secondary hypertriglyceridaemia. Curr Drug Targets. 2009;10(4):336–43.
  CAS PubMed Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345–61.
  CAS PubMed PubMed Central Google Scholar
• Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids. 2010;45(10):907–14.
  CAS PubMed PubMed Central Google Scholar
• Krishnamurthy V, Kerekoppa AR, Prabhakar B. Cross-sectional study of pattern of dyslipidemia and prevalence of atherogenic diabetic dyslipidemia in newly detected diabetic patients. Asian J Med Sci. 2019;10(6):45–9.
  Google Scholar
• Gudbjartsson DF, Thorgeirsson G, Sulem P, Helgadottir A, Gylfason A, Saemundsdottir J, et al. Lipoprotein (a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol. 2019;74(24):2982–94.
  CAS PubMed Google Scholar
• Vergès B. Lipid modification in type 2 diabetes: the role of LDL and HDL. Fundam Clin Pharmacol. 2009;23(6):681–5.
  PubMed Google Scholar
• Femlak M, Gluba-Brzózka A, Ciałkowska-Rysz A, Rysz J. The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk. Lipids Health Dis. 2017;16(1):1–9.
  Google Scholar
• Younis NN, Durrington PN. HDL functionality in diabetes mellitus: potential importance of glycation. Clin Lipidol. 2012;7(5):561–78.
  CAS Google Scholar
• Ganjali S, Dallinga-Thie GM, Simental-Mendía LE, Banach M, Pirro M, Sahebkar A. HDL functionality in type 1 diabetes. Atherosclerosis. 2017;267:99–109.
  CAS PubMed Google Scholar
• Farbstein D, Levy AP. HDL dysfunction in diabetes: causes and possible treatments. Expert Rev Cardiovasc Ther. 2012;10(3):353–61.
  CAS PubMed PubMed Central Google Scholar
• Lee JS, Chang PY, Zhang Y, Kizer JR, Best LG, Howard BV. Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status: the Strong Heart Study. Diabetes care. 2017;40(4):529–37.
  PubMed PubMed Central Google Scholar
• Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Extreme lipoprotein (a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013;61(11):1146–56.
  CAS PubMed Google Scholar
• Willeit P, Kiechl S, Kronenberg F, Witztum JL, Santer P, Mayr M, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein (a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014;64(9):851–60.
  PubMed Google Scholar
• Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.
  PubMed Google Scholar
• Zhang HW, Zhao X, Guo YL, Gao Y, Zhu CG, Wu NQ, et al. Elevated lipoprotein (a) levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2018;28(10):980–6.
  PubMed Google Scholar
• Singla S, Kaur K, Kaur G, Kaur H, Kaur J, Jaswal S. Lipoprotein (a) in type 2 diabetes mellitus: relation to LDL: HDL ratio and glycemic control. Int J Diabetes Dev Ctries. 2009;29(2):80.
  PubMed PubMed Central Google Scholar
• Hermans MP, Ahn SA, Rousseau MF. The mixed benefit of low lipoprotein (a) in type 2 diabetes. Lipids Health Dis. 2017;16(1):171.
  PubMed PubMed Central Google Scholar
• Zhang P, Gao J, Pu C, Zhang Y. Apolipoprotein status in type 2 diabetes mellitus and its complications. Mol Med Rep. 2017;16(6):9279–86.
  CAS PubMed Google Scholar
• Kanani FH, Alam JM. Apolipoprotein B in type 2 diabetics—a cross sectional study in a tertiary care set-up. J Pak Med Assoc. 2010;60(8):653.
  PubMed Google Scholar
• Lee B, Pratumvinit B, Thongtang N. The role of apoB measurement in type 2 diabetic patients. Clin Lipidol. 2015;10(2):137–44.
  CAS Google Scholar
• Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(s2):1–87.
  PubMed Google Scholar
• Chawla R, Madhu SV, Makkar BM, Ghosh S, Saboo B, Kalra S. RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian J Endocr Metab. 2020;24:1–122.
  Google Scholar
• Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–143.
  PubMed Google Scholar
• O’Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol. 2007;100(5):899–904.
  PubMed Google Scholar
• Langsted A, Nordestgaard BG. Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. Clin Chem. 2011;57(3):482–9.
  CAS PubMed Google Scholar
• Nakamura K, Miyoshi T, Yunoki K, Ito H. Postprandial hyperlipidemia as a potential residual risk factor. J Cardiol. 2016;67(4):335–9.
  PubMed Google Scholar
• Anderson TJ, Mancini GJ, Genest J Jr, Grégoire J, Lonn EM, Hegele RA. The new dyslipidemia guidelines: what is the debate? Can J Cardiol. 2015;31(5):605–12.
  PubMed Google Scholar
• de Vries MA. Novel pro-and anti-atherogenic effects of apolipoprotein B-containing lipoproteins: To feast or to fast? 2017.
• Nordestgaard BG. A test in context: lipid profile, fasting versus nonfasting. J Am Coll Cardiol. 2017 Sep 18;70(13):1637–46.
  PubMed Google Scholar
• Rahman F, Blumenthal RS, Jones SR, Martin SS, Gluckman TJ, Whelton SP. Fasting or non-fasting lipids for atherosclerotic cardiovascular disease risk assessment and treatment? Curr Atheroscler Rep. 2018;20(3):14.
  PubMed Google Scholar
• Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37(25):1944–58.
  PubMed PubMed Central Google Scholar
• Aldasouqi S, Sheikh A, Klosterman P, Kniestedt S, Schubert L, Danker R, et al. Hypoglycemia in patients with diabetes on antidiabetic medications who fast for laboratory tests. Diabetes Care. 2011;34(5):e52.
  PubMed PubMed Central Google Scholar
• Mancini GJ, Hegele RA, Leiter LA. Dyslipidemia. Can J Diabetes. 2018;42:S178–85.
  PubMed Google Scholar
• Sathiyakumar V, Park J, Golozar A, Lazo M, Quispe R, Guallar E, et al. Fasting versus nonfasting and low-density lipoprotein cholesterol accuracy. Circulation. 2018;137(1):10–9.
  CAS PubMed Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;63(25 Part B):2889–934.
  PubMed Google Scholar
• Driver SL, Martin SS, Gluckman TJ, Clary JM, Blumenthal RS, Stone NJ. Fasting or nonfasting lipid measurements: it depends on the question. J Am Coll Cardiol. 2016;67(10):1227–34.
  CAS PubMed Google Scholar
• Yoshida H. Determination of fasting and non-fasting cholesterol levels of low-and high-density lipoproteins with homogenous assays: a promising reliable way to assessment of dyslipidemia. J Atheroscler Thromb. 2017;24(6):569–71.
  PubMed PubMed Central Google Scholar
• Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation. 2008;118(10):993.
  CAS PubMed PubMed Central Google Scholar
• Doran B, Guo Y, Xu J, Weintraub H, Mora S, Maron DJ, et al. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation. 2014;130(7):546–53.
  CAS PubMed Google Scholar
• Fatima S, Ijaz A, Sharif TB, Khan DA, Siddique A. Accuracy of non-fasting lipid profile for the assessment of lipoprotein coronary risk. J Coll Physicians Surg Pak. 2016;26:954–7.
  PubMed Google Scholar
• Andrade C. Nonfasting lipid profile may suffice to manage dyslipidemia. Indian J Psychol Med. 2020;42(3):316–7.
  PubMed PubMed Central Google Scholar
• Chamnan P, Simmons RK, Sharp SJ, Griffin SJ, Wareham NJ. Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia. 2009;52(10):2001.
  CAS PubMed PubMed Central Google Scholar
• D’agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care. Circulation. 2008;117(6):743–53.
  PubMed Google Scholar
• Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007;93(2):172–6.
  PubMed Google Scholar
• Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;23:357.
  Google Scholar
• Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105(3):310–5.
  PubMed Google Scholar
• Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297(6):611–9.
  CAS PubMed Google Scholar
• Ferrario M, Chiodini P, Chambless LE, Cesana G, Vanuzzo D, Panico S, et al. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol. 2005;34(2):413–21.
  PubMed Google Scholar
• Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’agostino RB, Gibbons R, et al. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;63(25 Part B):2935–59.
  PubMed Google Scholar
• Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA, et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol. 2015;3(5):339–55.
  PubMed Google Scholar
• Jahangiry L, Farhangi MA, Rezaei F. Framingham risk score for estimation of 10-years of cardiovascular diseases risk in patients with metabolic syndrome. J Health Popul Nutr. 2017;36(1):1–6.
  Google Scholar
• Stephens JW, Ambler G, Vallance P, Betteridge DJ, Humphries SE, Hurel SJ. Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? Eur J Cardiovasc Prev Rehabil. 2004;11(6):521–8.
  PubMed Google Scholar
• Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR, United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci. 2001;101(6):671–9.
  CAS Google Scholar
• QRISK®3 score [Website]. Version 2018.0. Last Updated on: 13th August 2018. Cited on: 19th April 2021. Available from: https://qrisk.org/three/index.php.
• Ghosal S, Sinha B, Ved J, Biswas M. Quantitative measure of asymptomatic cardiovascular disease risk in type 2 diabetes: evidence from Indian outpatient setting. Indian Heart J. 2020;72(2):119–22.
  PubMed PubMed Central Google Scholar
• Orringer CE, Blaha MJ, Blankstein R, Budoff MJ, Goldberg RB, Gill EA, et al. The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. J Clin Lipidol. 2021 Jan-Feb;15(1):33–60
• Elkeles RS, Godsland IF, Feher MD, Rubens MB, Roughton M, Nugara F, et al. Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. Eur Heart J. 2008;29(18):2244–51.
  CAS PubMed Google Scholar
• Raggi P, Shaw LJ, Berman DS, Callister TQ. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol. 2004;43:1663–9.
  CAS PubMed Google Scholar
• Anand DV, Lim E, Hopkins D, Corder R, Shaw LJ, Sharp P, et al. Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J. 2006;27:713–21.
  PubMed Google Scholar
• Young LH, Frans JT, Chyun DA, Davey JA, Barrett EJ, Taillefer R, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009;301(15):1547–55.
  CAS PubMed PubMed Central Google Scholar
• Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769–818.
  PubMed Google Scholar
• Wu H, Shang H, Wu J. Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2018;60(2):229–39.
  PubMed Google Scholar
• Kendall CW, Jenkins DJ. A dietary portfolio: maximal reduction of low-density lipoprotein cholesterol with diet. Curr Atheroscler Reports. 2004;6(6):492–8.
  Google Scholar
• Jenkins DJ, Kendall CW, Faulkner DA, Nguyen T, Kemp T, Marchie A, et al. Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. Am J Clin Nutr. 2006;83:582–91.
  CAS PubMed Google Scholar
• Kelley GA, Kelley KS. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Prev Med. 2009;48(1):9–19.
  CAS PubMed Google Scholar
• Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the study of obesity. Circulation. 2009;120(16):1640–5.
  CAS PubMed Google Scholar
• Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Look AHEAD Research Group, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–6.
  CAS PubMed PubMed Central Google Scholar
• American Diabetes Association. 5. Facilitating behavior change and well-being to improve health outcomes: standards of Medical Care in Diabetes 2021. Diabetes Care. 2021;44(Suppl. 1):S53–72.
  Google Scholar
• Shantakumari N, Sequeira S. Effects of a yoga intervention on lipid profiles of diabetes patients with dyslipidemia. Indian Heart J. 2013;65(2):127–31.
  PubMed PubMed Central Google Scholar
• Gordon L, McGrowder DA, Pena YT, Cabrera E, Lawrence-Wright M. Effect of exercise therapy on lipid parameters in patients with end-stage renal disease on hemodialysis. J Lab Physicians. 2012;4(1):17.
  CAS PubMed PubMed Central Google Scholar
• Nagarathna R, Tyagi R, Kaur G, Vendan V, Acharya IN, Anand A, et al. Efficacy of a validated yoga protocol on dyslipidemia in diabetes patients: NMB-2017 India trial. Medicines. 2019;6(4):100.
  CAS PubMed Central Google Scholar
• Cappuccio FP, Cooper D, D'Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J. 2011;32(12):1484–92.
  PubMed Google Scholar
• Boehm JK, Williams DR, Rimm EB, Ryff C, Kubzansky LD. Relation between optimism and lipids in midlife. Am J Cardiol. 2013;111(10):1425–31.
  CAS PubMed PubMed Central Google Scholar
• Evert AB, Dennison M, Gardner CD, Garvey WT, Lau KH, MacLeod J, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019;42(5):731–54.
  PubMed PubMed Central Google Scholar
• Myers EF, Trostler N, Varsha V, Voet H. Insights from the Diabetes in India Nutrition Guidelines Study: adopting innovations using a knowledge transfer model. Top Clin Nutr. 2017;32(1):69.
  PubMed PubMed Central Google Scholar
• Marincic PZ, Salazar MV, Hardin A, Scott S, Fan SX, Gaillard PR, et al. Diabetes self-management education and medical nutrition therapy: a multisite study documenting the efficacy of registered dietitian nutritionist interventions in the management of glycemic control and diabetic dyslipidemia through retrospective chart review. J Acad Nutr Diet. 2019;119(3):449–63.
  PubMed Google Scholar
• Hegele RA, Gidding SS, Ginsberg HN, McPherson R, Raal FJ, Rader DJ, et al. Nonstatin low-density lipoprotein–lowering therapy and cardiovascular risk reduction—statement from ATVB council. Arterioscler, Thromb, Vasc Biol. 2015;35(11):2269–80.
  CAS Google Scholar
• Trialists CT. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–25.
  Google Scholar
• Wang N, Fulcher J, Abeysuriya N, Park L, Kumar S, Di Tanna GL, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327,037 participants. Lancet Diabetes Endocrinol. 2020;8(1):36–49.
  PubMed Google Scholar
• Hadjiphilippou S, Ray KK. Cholesterol-lowering agents: statins—for everyone? Circ Res. 2019;124(3):354–63.
  CAS PubMed Google Scholar
• Khalil S, Khayyat S, Al-Khadra Y, Alraies MC. Should all diabetic patients take statin therapy regardless of serum cholesterol level? Expert Rev Cardiovasc Ther. 2019;17(4):237–9.
  CAS PubMed Google Scholar
• Naeem F, McKay G, Fisher M. Cardiovascular outcomes trials with statins in diabetes. Br J Diabetes. 2018;18(1):7–13.
  Google Scholar
• Armani A, Toth PP. The CARDS trial: diabetic patients dealt a winning hand. Curr Atheroscler Rep. 2006;8(5):429–32.
  CAS PubMed Google Scholar
• Karlson BW, Barter PJ, Palmer MK, Lundman P, Nicholls SJ. Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER. Nutr Metab Cardiovasc Dis. 2012;22(9):697–703.
  CAS PubMed Google Scholar
• Kawai Y, Sato-Ishida R, Motoyama A, Kajinami K. Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus. Drug Des Devel Ther. 2011;5:283.
  CAS PubMed PubMed Central Google Scholar
• Barrios V, Escobar C. Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes. Future Cardiol. 2016;12(4):449–66.
  CAS PubMed Google Scholar
• Martín-Timón I, Sevillano-Collantes C, García-Domínguez M, Marín-Peñalver JJ, Ugalde-Abiega B, del Cañizo-Gómez FJ. Update on the management of diabetic dyslipidaemia. EMJ Diabet. 2018;6(1):53–61.
  Google Scholar
• Masana L. Pitavastatin in cardiometabolic disease: therapeutic profile. Cardiovasc Diabetol. 2013;12(1):1–8.
  Google Scholar
• Mita T, Nakayama S, Abe H, Gosho M, Iida H, Hirose T, et al. Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia. J Diabetes Investig. 2013;4(3):297–303.
  CAS PubMed PubMed Central Google Scholar
• Gumprecht J, Gosho M, Budinski D, Hounslow N. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20–40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab. 2011;13(11):1047–55.
  CAS PubMed Google Scholar
• Hoy SM. Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017;17(2):157–68.
  CAS PubMed Google Scholar
• Patil CY, Baig MS, Doifode SM. Assessing the efficacy and safety of pitavastatin compared to atorvastatin in dyslipidemic patients: a double blind randomized controlled trial. Int J Basic Clin Pharmacol. 2016;5:834–40.
  Google Scholar
• Jayakumari C, Jabbar PK, Soumya S, Jayakumar RV, Das DV, Girivishnu G, et al. Lipid profile in Indian patients with type 2 diabetes: the scope for atherosclerotic cardiovascular disease risk reduction. Diabetes Spectr. 2020;33(4):299–306.
  PubMed PubMed Central Google Scholar
• Stulc T, Ceška R, Gotto AM. Statin intolerance: the clinician’s perspective. Curr Atheroscler Rep. 2015;17(12):1–7.
  CAS Google Scholar
• Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to statins: mechanisms and management. Diabetes Care. 2013;36(Supplement 2):S325–30.
  CAS PubMed PubMed Central Google Scholar
• Alonso R, Cuevas A, Cafferata A. Diagnosis and management of statin intolerance. J Atheroscler Thromb. 2019 Mar 1;26(3):207–15.
  CAS PubMed PubMed Central Google Scholar
• Ferreira AM, da Silva PM. Defining the place of ezetimibe/atorvastatin in the management of hyperlipidemia. Am J Cardiovasc Drugs. 2017 Jun;17(3):169–81.
  CAS PubMed Google Scholar
• Barkas F, Elisaf M, Liberopoulos E, Klouras E, Liamis G, Rizos EC. Statin therapy with or without ezetimibe and the progression to diabetes. J Clin Lipidol. 2016 Mar 1;10(2):306–13.
  PubMed Google Scholar
• Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015;132(13):1224–33.
  CAS PubMed Google Scholar
• Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018 Apr 10;137(15):1571–82.
  CAS PubMed Google Scholar
• Sakamoto K, Kawamura M, Watanabe T, Ashidate K, Kohro T, Tanaka A, et al. Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids Health Dis. 2017 Dec;16(1):1–9.
  Google Scholar
• Lee J, Hwang YC, Lee WJ, Won JC, Song KH, Park CY, et al. Comparison of the efficacy and safety of rosuvastatin/ezetimibe combination therapy and rosuvastatin monotherapy on lipoprotein in patients with type 2 diabetes: multicenter randomized controlled study. Diabetes Ther. 2020 Feb;17:1–3.
  Google Scholar
• Hong N, Lee YH, Tsujita K, Gonzalez JA, Kramer CM, Kovarnik T, et al. Comparison of the effects of ezetimibe-statin combination therapy on major adverse cardiovascular events in patients with and without diabetes: a meta-analysis. Endocrinol Metab. 2018 Jun;33(2):219.
  CAS Google Scholar
• Wang X, Zhang Y, Tan H, Wang P, Zha X, Chong W, et al. Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2020 Dec;19(1):1–9.
  CAS Google Scholar
• Cicero AF, Fogacci F, Hernandez AV, Banach M. Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert Panel (ILEP). Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis. PLoS Med. 2020;17(7):e1003121.
  CAS PubMed PubMed Central Google Scholar
• Laufs U, Banach M, Mancini GJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662.
  PubMed PubMed Central Google Scholar
• Leiter L, Banach M, Catapano A, Duell P, Gotto A, Laufs U, et al. Bempedoic acid and glycemic control: a pooled analysis of 4 phase 3 clinical trials. J Clin Lipidol. 2020;14(4):577–9.
  Google Scholar
• Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of PCSK9 inhibitors. J Am Coll Cardiol. 2018;72(3):314–29.
  CAS PubMed Google Scholar
• Monami M, Sesti G, Mannucci E. PCSK9 inhibitor therapy: a systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes. Diabetes Obes Metab. 2019;21(4):903–8.
  PubMed Google Scholar
• Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2021;37:1129–50.
  PubMed Google Scholar
• Orringer CE, Jacobson TA, Saseen JJ, Brown AS, Gotto AM, Ross JL, et al. Update on the use of PCSK9 inhibitors in adults: recommendations from an Expert Panel of the National Lipid Association. J Clin Lipidol. 2017;11(4):880–90.
  PubMed Google Scholar
• Handelsman Y, Lepor NE. PCSK9 inhibitors in lipid management of patients with diabetes mellitus and high cardiovascular risk: a review. J Am Heart Assoc. 2018;7(13):e008953.
  CAS PubMed PubMed Central Google Scholar
• Kosmas CE, Skavdis A, Sourlas A, Papakonstantinou EJ, Genao EP, Uceta RE, et al. Safety and tolerability of PCSK9 inhibitors: current insights. Clin Pharmacol. 2020;12:191.
  CAS PubMed PubMed Central Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Eng J Med. 2017;376(18):1713–22.
  CAS Google Scholar
• Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941–50.
  CAS PubMed Google Scholar
• Ray KK, Leiter LA, Müller-Wieland D, Cariou B, Colhoun HM, Henry RR, et al. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: the ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes Obes Metab. 2018;20(6):1479–89.
  CAS PubMed PubMed Central Google Scholar
• Khan SU, Rahman H, Okunrintemi V, Riaz H, Khan MS, Sattur S, et al. Association of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering therapies and risk of diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2019;8(7):e011581.
  PubMed PubMed Central Google Scholar
• Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus–a pooled meta-analysis of randomized placebo-controlled clinical trials. Int J Cardiol. 2010;141(2):157–66.
  PubMed Google Scholar
• Hiukka A, Leinonen E, Jauhiainen M, Sundvall J, Ehnholm C, Keech AC, et al. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia. 2007;50(10):2067–75.
  CAS PubMed Google Scholar
• Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017;2(4):370–80.
  PubMed Google Scholar
• d’Emden MC, Jenkins AJ, Li L, Zannino D, Mann KP, Best JD, et al. Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2014;57(11):2296–303.
  PubMed Google Scholar
• Tsunoda F, Asztalos IB, Horvath KV, Steiner G, Schaefer EJ, Asztalos BF. Fenofibrate, HDL, and cardiovascular disease in type-2 diabetes: the DAIS trial. Atherosclerosis. 2016;247:35–9.
  CAS PubMed PubMed Central Google Scholar
• Joshi SR. Saroglitazar for the treatment of dyslipidemia in diabetic patients. Expert Opin Pharmacother. 2015;16(4):597–606.
  CAS PubMed Google Scholar
• Sai VN, Pasula S, Sumathi S, Sreekanth M, Rao AS, Prasad BD. The clinical aspects of saroglitazar and its side effects. J Drug Deliv Ther. 2020;10(2):208–12.
  CAS Google Scholar
• Kaul U, Parmar D, Manjunath K, Shah M, Parmar K, Patil KP, et al. New dual peroxisome proliferator activated receptor agonist—saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. Cardiovasc Diabetol. 2019;18(1):1–1.
  CAS Google Scholar
• Krishnappa M, Patil K, Parmar K, Trivedi P, Mody N, Shah C, et al. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study). Cardiovasc Diabetol. 2020;19(1):1–3.
  Google Scholar
• Backes J, Anzalone D, Hilleman D, Catini J. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids Health Dis. 2016;15(1):1–2.
  Google Scholar
• Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013;12(1):1-0.
• Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol. 2019;73(22):2791–802.
  CAS PubMed Google Scholar
• Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Eng J Med. 2019;380(1):11–22.
  CAS Google Scholar
• Natto ZS, Yaghmoor W, Alshaeri HK, Van Dyke TE. Omega-3 fatty acids effects on inflammatory biomarkers and lipid profiles among diabetic and cardiovascular disease patients: a systematic review and meta-analysis. Sci Rep. 2019;9(1):1-0.
• Sunil B, Ashraf AP. Dyslipidemia in pediatric type 2 diabetes mellitus. Curr Diab Rep. 2020;20(10):1–9.
  Google Scholar
• Zeitler P, Arslanian S, Fu J, Pinhas-Hamiel O, Reinehr T, Tandon N, et al. ISPAD clinical practice consensus guidelines 2018: type 2 diabetes mellitus in youth. Paedr diabetes. 2018;19:28–46.
  Google Scholar
• American Diabetes Association. 13, Children and adolescents: standards of medical care in diabetes− 2020. Diabetes Care. 2020;43(Supplement 1):S163–82.
• Barrett HL, Nitert MD, McIntyre HD, Callaway LK. Normalizing metabolism in diabetic pregnancy: is it time to target lipids? Diabetes Care. 2014;37(5):1484–93.
  CAS PubMed Google Scholar
• Wild R, Weedin EA, Wilson D. Dyslipidemia in pregnancy. Cardiology clinics. 2015;33(2):209–15.
  PubMed Google Scholar
• Trialists CT. Articles Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393:407–15.
  Google Scholar
• Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396(10263):1637–43.
  CAS PubMed PubMed Central Google Scholar
• Ponce OJ, Larrea-Mantilla L, Hemmingsen B, Serrano V, Rodriguez-Gutierrez R, Spencer-Bonilla G, et al. Lipid-lowering agents in older individuals: a systematic review and meta-analysis of randomized clinical trials. J Clin Endocrinol Metab. 2019;104(5):1585–94.
  PubMed Google Scholar
• Matsuzaka T, Shimano H. New perspective on type 2 diabetes, dyslipidemia and non-alcoholic fatty liver disease. J Diabetes Investig. 2020;11(3):532–4.
  PubMed PubMed Central Google Scholar
• Marcum ZA, Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother. 2012;10(4):264–71.
  CAS PubMed PubMed Central Google Scholar
• Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287–92.
  CAS PubMed Google Scholar
• Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63:705–12.
  CAS PubMed Google Scholar
• Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, et al. Adverse effects of statin therapy: perception vs. the evidence–focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526–39.
  CAS PubMed PubMed Central Google Scholar
• Bays HE, Cohen DE, Chalasani N, Harrison SA. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014;8:S47–57.
  PubMed Google Scholar
• Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis. World J Gastroenterol. 2018;24(30):3361–73.
  PubMed PubMed Central Google Scholar
• Gawrieh S, Noureddin M, Loo NM, Mohseni R, Awasty VR, Cusi K, et al. A phase 2, prospective, multicenter, double-blind, randomized study of saroglitazar magnesium 1 mg, 2 mg or 4 mg versus placebo in patients with nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis (EVIDENCES IV). Hepatology. 2019;70(6):1484A–5A.
  Google Scholar
• Goyal O, Nohria S, Goyal P, Kaur J, Sharma S, Sood A, et al. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Scientific Reports. 2020;10(1):1–9.
  Google Scholar
• Teramoto T. Pitavastatin: clinical effects from the LIVES Study. Atheroscler Suppl. 2011;12(3):285–8.
  CAS PubMed Google Scholar
• Wu Y, Wang Y, An C, Dong Z, Liu H, Zhang Y, et al. Effects of rosuvastatin and atorvastatin on renal function–meta-analysis. Circulation J. 2012;76(5):1259–66.
  CAS Google Scholar
• Rangel ÉB, de Sá JR, Melaragno CS, Gonzalez AM, Linhares MM, Salzedas A, et al. Kidney transplant in diabetic patients: modalities, indications and results. Diabetol Metab Syndr. 2009;1(1):1–7.
  Google Scholar
• Breda A, Budde K, Figueiredo A, García EL, Olsburgh J, Regele H, et al. EAU guidelines on renal transplant – update 2021. Edn. presented at the EAU Annual Congress Milan Italy 2021. ISBN 978-94-92671-13-4.
• Scicchitano P, Milo M, Mallamaci R, De Palo M, Caldarola P, Massari F, et al. Inclisiran in lipid management: a literature overview and future perspectives. Biomed Pharmacother. 2021;143:112227.
  CAS PubMed Google Scholar
• Wright RS, Collins MG, Stoekenbroek RM, Robson R, Wijngaard PL, Landmesser U, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies. InMayo Clinic Proceedings. 2020;95(1):77–89.
  Google Scholar
• Leiter LA, Teoh H, Kallend D, Wright RS, Landmesser U, Wijngaard PL, et al. Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial. Diabetes Care. 2019;42(1):173–6.
  CAS PubMed Google Scholar